Mark Jennings, MD
Internal Medicine · Allen, TXNPI 1336379783
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,642 of the $3,977 with a category attached, or 66.4%. 41 manufacturers reported payments, led by Pfizer at 31.3% of the total.
Across 206 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- AstraZeneca$398
- Novartis$215
- Caris MPI, Inc.$141
- Merck$135
- E.r. Squibb & Sons, L.L.C.$134
- plus $2K from 35 others
Across 32 payments — averaging $2637.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$44K
- GSK$32K
- E.r. Squibb & Sons, L.L.C.$6K
- Spectrum Pharmaceuticals Inc.$3K
What the payments were for
- Speaking & faculty fees$1504%
- Food & beverage$2,64266%
- Education$1,18530%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 90 | $1,246 |
| AstraZeneca(2 entities) | 9 | $398 |
| Novartis | 11 | $215 |
| Caris MPI, Inc. | 2 | $141 |
| Merck | 9 | $135 |
| E.r. Squibb & Sons, L.L.C. | 6 | $134 |
| Intuitive Surgical | 1 | $130 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $105 |
| Bayer | 5 | $104 |
| Astellas Pharma US Inc | 6 | $92 |
| AbbVie | 5 | $90 |
| Genentech USA, Inc. | 6 | $88 |
| Veran Medical Technologies, Inc. | 1 | $84 |
| GSK | 5 | $83 |
| Ipsen Biopharmaceuticals, Inc | 5 | $81 |
| Sanofi | 3 | $72 |
| Taiho Oncology, Inc. | 3 | $60 |
| Seagen Inc. | 4 | $56 |
| Regeneron Healthcare Solutions, Inc. | 2 | $55 |
| Beone Medicines USA, Inc. | 2 | $52 |
| Johnson & Johnson(2 entities) | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Gilead | 3 | $48 |
| Bristol Myers Squibb | 2 | $42 |
| Karyopharm Therapeutics Inc. | 1 | $35 |
| Genmab U.S., Inc. | 1 | $33 |
| Recordati_rare_diseases_inc. | 1 | $32 |
| ADC Therapeutics America, Inc. | 1 | $29 |
| Lilly USA, LLC | 2 | $27 |
| Boehringer Ingelheim | 1 | $26 |
| Daiichi Sankyo Inc. | 2 | $24 |
| Pharmaessentia USA Corporation | 1 | $23 |
| Array Biopharma Inc | 1 | $18 |
| Beigene USA, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Blue Earth Diagnostics | 1 | $16 |
| EMD Serono, Inc. | 1 | $16 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIRIS$150
- MI CANCER SEEK$137
- Da Vinci Surgical System$130
- CALQUENCE$125
- IMBRUVICA$105
How this compares
$3,977 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 54 | $900,290 |
| RevlimidLenalidomide | 38 | $800,831 |
| BrukinsaZanubrutinib | 28 | $400,129 |
| Lenalidomide | 23 | $355,061 |
| PomalystPomalidomide | 17 | $350,451 |
| TagrissoOsimertinib Mesylate | 21 | $336,739 |
| TasignaNilotinib Hcl | 16 | $328,755 |
| InrebicFedratinib Dihydrochloride | 12 | $325,058 |
| VenclextaVenetoclax | 27 | $290,164 |
| CalquenceAcalabrutinib Maleate | 21 | $284,733 |
| LenvimaLenvatinib Mesylate | 11 | $267,346 |
| XtandiEnzalutamide | 17 | $234,569 |
| PromactaEltrombopag Olamine | 11 | $213,314 |
| XareltoRivaroxaban | 46 | $34,896 |
| EliquisApixaban | 57 | $32,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Inrebic | $42 | $1,125,89050 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $105 | $900,29054 claims |
| AstraZenecaTagrisso, Calquence | $398 | $621,47242 claims |
| NovartisTasigna, Promacta | $215 | $542,07027 claims |
| Beigene USA, Inc.Brukinsa | $18 | $400,12928 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $134 | $350,45117 claims |
| AbbVieVenclexta | $90 | $290,16427 claims |
| Eisai Inc.Lenvima | $11 | $267,34611 claims |
| Astellas Pharma US IncXtandi | $92 | $234,56917 claims |
| Johnson & JohnsonXarelto | $51 | $34,89646 claims |
| PfizerEliquis | $1,246 | $32,01357 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $50 | $58970 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Allen
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.